

Caroline Bodet-Milin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6328741/publications.pdf>

Version: 2024-02-01

108
papers

3,477
citations

126907

33
h-index

155660

55
g-index

114
all docs

114
docs citations

114
times ranked

4216
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic value of FDG-PET/CT response for patient selection before chimeric antigen receptor-T cells therapy in non-Hodgkin lymphoma. <i>Hematological Oncology</i> , 2022, 40, 796-800.	1.7	6
2	Molecular Signature of ¹⁸ F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1008-1013.	5.0	4
3	Standardization of ¹⁸ F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 116-125.	1.6	85
4	Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1005-1015.	6.4	35
5	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	1.4	48
6	Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1221-1227.	5.0	12
7	Whole-body MR imaging in suspected physical child abuse: comparison with skeletal survey and bone scintigraphy findings from the PEDIMA prospective multicentre study. <i>European Radiology</i> , 2021, 31, 8069-8080.	4.5	8
8	Cardiac Metastasis from Medullary Thyroid Cancers with Long-Term Survival under Vandetanib. <i>European Thyroid Journal</i> , 2021, 10, 1-6.	2.4	2
9	Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2020, 15, 129-139.	2.8	22
10	Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. <i>Haematologica</i> , 2020, 105, e33-e36.	3.5	31
11	Good clinical practice recommendations for the use of PET/CT in oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 28-50.	6.4	85
12	Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases. <i>Biomedicines</i> , 2020, 8, 548.	3.2	8
13	Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 5607-5615.	5.2	222
14	Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5406.	4.1	13
15	Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. <i>Cancers</i> , 2020, 12, 2532.	3.7	17
16	ImmunoPET in Multiple Myeloma—What? So What? Now What?. <i>Cancers</i> , 2020, 12, 1467.	3.7	8
17	FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?. <i>Cancers</i> , 2020, 12, 1384.	3.7	6
18	SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human. <i>Frontiers in Oncology</i> , 2020, 10, 20.	2.8	0

#	ARTICLE	IF	CITATIONS
19	Imaging of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. <i>Cancers</i> , 2020, 12, 486.	3.7	8
20	Reply to E. Laffon <i>et al</i> .. <i>Haematologica</i> , 2020, 105, e42-e42.	3.5	0
21	Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study. <i>Blood</i> , 2020, 136, 26-26.	1.4	0
22	FDG PET in Multiple Myeloma. , 2019, , 27-38.		2
23	Potential for Nuclear Medicine Therapy for Glioblastoma Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 772.	3.5	31
24	Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. <i>Cancers</i> , 2019, 11, 1282.	3.7	43
25	Radioimmunotherapy of Lymphomas. , 2019, , 113-121.		3
26	Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches. <i>Frontiers in Medicine</i> , 2019, 6, 124.	2.6	20
27	What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between ⁸⁹ Zr- and ⁶⁴ Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2564.	4.1	22
28	[¹⁸ F]-Fludarabine for Hematological Malignancies. <i>Frontiers in Medicine</i> , 2019, 6, 77.	2.6	9
29	Interest of FDG-PET in the Management of Mantle Cell Lymphoma. <i>Frontiers in Medicine</i> , 2019, 6, 70.	2.6	13
30	Interest of Pet Imaging in Multiple Myeloma. <i>Frontiers in Medicine</i> , 2019, 6, 69.	2.6	34
31	¹⁸ F-FDG PET/CT in multiple myeloma: critical insights and future directions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1048-1050.	6.4	1
32	Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 906-911.	2.0	6
33	Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 222-225.	1.3	11
34	Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study. <i>Blood</i> , 2019, 134, 692-692.	1.4	42
35	¹⁸ F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1380-1385.	5.0	15
36	Comparison of Immuno-PET of CD138 and PET imaging with ⁶⁴ CuCl ₂ and ¹⁸ F-FDG in a preclinical syngeneic model of multiple myeloma. <i>Oncotarget</i> , 2018, 9, 9061-9072.	1.8	29

#	ARTICLE	IF	CITATIONS
37	Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of $\hat{\tau}$ SUVmax in the FDG-Avid Patients of the IMAJEM Study. <i>Clinical Cancer Research</i> , 2018, 24, 5219-5224.	7.0	24
38	Prospects for Enhancing Efficacy of Radioimmunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 139-153.	0.1	1
39	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. <i>Blood</i> , 2018, 132, 257-257.	1.4	20
40	Sensitivity of pretargeted immunoPET using ^{68}Ga -peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT. <i>Oncotarget</i> , 2018, 9, 27502-27513.	1.8	12
41	Report of the 6th International Workshop on PET in lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2298-2303.	1.3	21
42	Radioimmunoconjugates for treating cancer: recent advances and current opportunities. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 813-819.	3.1	27
43	Consolidation anti-CD22 fractionated radioimmunotherapy with ^{90}Y -epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45.	4.6	33
44	Pretargeting for imaging and therapy in oncological nuclear medicine. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 2, 6.	3.9	41
45	Immuno-PET for Clinical Theranostic Approaches. <i>International Journal of Molecular Sciences</i> , 2017, 18, 57.	4.1	50
46	PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 445.	4.1	23
47	Prospective Evaluation of Magnetic Resonance Imaging and [^{18}F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2911-2918.	1.6	247
48	Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. <i>PLoS ONE</i> , 2017, 12, e0183841.	2.5	22
49	Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?. <i>Current Cancer Therapy Reviews</i> , 2016, 12, 54-65.	0.3	3
50	Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and ^{68}Ga -Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1505-1511.	5.0	61
51	Radioimmunotherapy for Treatment of Acute Leukemia. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 135-146.	4.6	31
52	Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials. <i>PLoS ONE</i> , 2016, 11, e0159984.	2.5	61
53	Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. <i>Frontiers in Medicine</i> , 2015, 2, 84.	2.6	29
54	A pretargeting system for tumor PET imaging and radioimmunotherapy. <i>Frontiers in Pharmacology</i> , 2015, 6, 54.	3.5	41

#	ARTICLE	IF	CITATIONS
55	Tumor Immunotargeting Using Innovative Radionuclides. International Journal of Molecular Sciences, 2015, 16, 3932-3954.	4.1	51
56	90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematology, the, 2015, 2, e108-e117.	4.6	36
57	Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group. Blood, 2015, 126, 335-335.	1.4	6
58	18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study. Bone Marrow Transplantation, 2014, 49, 131-137.	2.4	30
59	Clinical NECR in 18F-FDG PET scans: optimization of injected activity and variable acquisition time. Relationship with SNR. Physics in Medicine and Biology, 2014, 59, 6417-6430.	3.0	25
60	Radioimmunoconjugates for the Treatment of Cancer. Seminars in Oncology, 2014, 41, 613-622.	2.2	65
61	Fractionated ⁹⁰ Y-lbritumomab Tixetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. Journal of Clinical Oncology, 2014, 32, 212-218.	1.6	57
62	Prognostic Value and Clinical Impact of 18FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy. Frontiers in Medicine, 2014, 1, 54.	2.6	17
63	Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. EJNMMI Research, 2013, 3, 11.	2.5	67
64	⁹⁰ Y-BCR-ABL ⁺ 1 molecular remission after ⁹⁰ Y-epratuzumab tetraxetan radioimmunotherapy in ⁹⁰ Y-CD22 ⁺ ALL: proof of principle. European Journal of Haematology, 2013, 91, 552-556.	2.2	19
65	La place de la TEP au FDG dans l'évaluation des lymphomes en 2012. Diagnostic and Interventional Imaging, 2013, 94, 164-174.	0.0	0
66	Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Frontiers in Oncology, 2013, 3, 177.	2.8	30
67	Improvement of Radioimmunotherapy Using Pretargeting. Frontiers in Oncology, 2013, 3, 159.	2.8	30
68	Radionuclide Metabolic Therapy. , 2013, , .		0
69	Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan. Medical Radiology, 2012, , 551-556.	0.1	1
70	18F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas. Nuclear Medicine Communications, 2012, 33, 1089-1095.	1.1	71
71	Modélisation du taux de comptage en TEP à partir de données cliniques: une voie robuste pour l'optimisation des paramètres d'acquisition?. Medecine Nucleaire, 2012, 36, 209-214.	0.2	0
72	Les outils de médecine nucléaire pour le développement de la médecine personnalisée dans le cancer du sein. Medecine Nucleaire, 2012, 36, 233-236.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study. <i>Blood</i> , 2012, 120, 152-152.	1.4	13
74	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. <i>Blood</i> , 2012, 120, 906-906.	1.4	5
75	Consolidation par 90Y-epratuzumab en fractionnement dans le lymphome B diffus à grandes cellules: résultats préliminaires d'une étude de phase II. <i>Medecine Nucleaire</i> , 2011, 35, 478-486.	0.2	0
76	Évaluation de la réponse thérapeutique par tomographie par émission de positons (TEP) au 18fluoro-désoxyglucose (FDG) en oncologie-hématologie. <i>Medecine Nucleaire</i> , 2011, 35, 600-607.	0.2	5
77	Radiothérapie vectorisée: les nouvelles molécules. <i>Medecine Nucleaire</i> , 2011, 35, 613-616.	0.2	1
78	Vertebral Osteomyelitis: An Unusual Presentation of Bartonella henselae Infection. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 511-516.	3.4	24
79	Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1064-1071.	6.4	87
80	Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. <i>Bone Marrow Transplantation</i> , 2011, 46, 393-399.	2.4	24
81	18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. <i>Annals of Oncology</i> , 2011, 22, 705-711.	1.2	54
82	Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1270-1278.	6.4	42
83	Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1633-1642.	6.4	76
84	Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. <i>Cancer</i> , 2010, 116, 1053-1058.	4.1	25
85	Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. <i>Cancer</i> , 2010, 116, 1093-1100.	4.1	33
86	High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3709-3716.	1.6	106
87	Comparative Toxicity and Efficacy of Combined Radioimmunotherapy and Antiangiogenic Therapy in Carcinoembryonic Antigen-Expressing Medullary Thyroid Cancer Xenograft. <i>Journal of Nuclear Medicine</i> , 2010, 51, 624-631.	5.0	19
88	L'imagerie TEP, une nouvelle approche d'imagerie moléculaire. <i>Medecine Nucleaire</i> , 2010, 34, 295-298.	0.2	1
89	Apport de la TEP/TDM au 18FDG dans la stadification initiale et l'évaluation précoce de la réponse thérapeutique des rhabdomyosarcomes pédiatriques. <i>Medecine Nucleaire</i> , 2010, 34, 655-663.	0.2	2
90	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients. <i>Blood</i> , 2010, 116, 2875-2875.	1.4	10

#	ARTICLE	IF	CITATIONS
91	Respective PROGNOSTIC Value of the International Harmonization PROJECT (IHP), Gallamini and London Criteria for Interim FDG PET-CT Performed AFTER 4 Courses of ABVD IN HODGKIN'S LYMPHOMA. Blood, 2010, 116, 3889-3889.	1.4	1
92	La place de l'ATTEP au FDG dans l'évaluation des lymphomes. Hematologie, 2009, 15, 305-312.	0.0	0
93	Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1813-1821.	6.4	111
94	La radio-immunothérapie. Medecine Nucleaire, 2009, 33, 148-151.	0.2	0
95	99mTc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonography. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 637-643.	6.4	44
96	La radio-immunothérapie en clinique. Medecine Nucleaire, 2008, 32, 254-257.	0.2	1
97	Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica, 2008, 93, 390-397.	3.5	45
98	FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica, 2008, 93, 1269-1271.	3.5	70
99	Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica, 2008, 93, 471-472.	3.5	130
100	Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery, 2007, 142, 952-958.	1.9	63
101	Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1556-1562.	6.4	27
102	Efficacy of FDG-PET/CT Imaging To Guide Biopsies in the Detection of Richter's Syndrome.. Blood, 2007, 110, 1390-1390.	1.4	0
103	Delayed Gastric Emptying Scintigraphy in Cystic Fibrosis Patients Before and After Lung Transplantation. Journal of Heart and Lung Transplantation, 2006, 25, 1077-1083.	0.6	58
104	Comparison of gastric emptying scintigraphy based on the geometric mean of the gastric proportion of the abdominal radioactivity or on the geometric mean of the intragastric radioactivity. Nuclear Medicine Communications, 2006, 27, 431-437.	1.1	8
105	FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Annals of Hematology, 2006, 85, 759-767.	1.8	61
106	Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. Journal of Nuclear Medicine, 2006, 47, 247-55.	5.0	88
107	FDG-PET Predicts Response to Fractionated Radioimmunotherapy with 90Y-Epratuzumab Anti-CD22 MAB in Patients with NHL.. Blood, 2005, 106, 4782-4782.	1.4	1
108	Gastric scintigraphy with a liquid-solid radiolabelled meal: performances of solid and liquid parameters. Nuclear Medicine Communications, 2004, 25, 1143-1150.	1.1	54